Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynamin 1 pseudogene 49 (DNM1P49) is annotated as a pseudogene in the human genome. Pseudogenes are genomic DNA sequences similar to normal genes but non-functional due to mutations or lack of regulatory elements. DNM1P49 is noted in gene databases, such as BioGPS and NCBI, as having no described protein product, biological function, disease association, or relevance as a drug target. Its aliases include DNM1DN8@, reflecting its annotation as a duplicated or non-functional copy related to the functional dynamin 1 gene DNM1, but there is no evidence it is transcribed or translated to perform any biological or pharmacological role[2]. Key Points and Supporting Context: - DNM1P49 is explicitly annotated as a **pseudogene** in databases[2]. Pseudogenes typically do not encode functional proteins and do not serve as drug targets or active biological entities. - There is **no published evidence** linking DNM1P49 to therapeutic targeting, disease roles, or any biological activity. - All references in the biomedical literature and gene databases relate either to the functional dynamin 1 gene (DNM1) or to similar pseudogenes, but not to DNM1P49 directly as a receptor, protein, or target[2]. - Related entries on dynamin family genes, such as DNM1 and DNM1L, describe functional roles in endocytosis and mitochondrial fission, but pseudogenes like DNM1P49 are not mentioned as functionally relevant[2]. Summary: DNM1P49 represents a non-coding, non-functional genetic element. It is not a therapeutic target, does not encode a functional protein, and should not be included in lists of active targets. Any attempt to use DNM1P49 as a canonical identifier for a molecular target is incorrect[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynamin 1 pseudogene 49 (DNM1P49).